In a development that could reshape feline health, researchers at the University of Florida are conducting a pilot study to assess the safety and efficacy of an implantable weight loss drug for cats. The medication, dubbed MEOW-1 – short for ManagEment of Over Weight cats – mimics the effects of popular human drugs like Ozempic, offering a potential new approach to tackling obesity in companion animals.
The study, which began in December 2025, currently involves approximately 50 obese cats. It comes as pet obesity rates continue to climb, with an estimated 60% of the 70 million cats in the U.S. Considered overweight or obese, according to study lead Dr. Chen Gilor. Approximately 600,000 cats in the United States are also diagnosed with diabetes, a condition often linked to excess weight.
MEOW-1 belongs to a class of drugs known as GLP-1 receptor agonists. These medications, initially developed to treat Type 2 diabetes in humans, work by mimicking a natural hormone released in the gut after eating. They regulate blood sugar, sluggish digestion, and reduce appetite. The rising use of GLP-1 drugs for weight management in humans is well-documented. a Gallup poll found that over 12% of U.S. Adults reported taking them for weight loss last year.
How the MEOW-1 Implant Works
Developed in partnership with San Francisco-based Okava Pharmaceuticals, MEOW-1 is administered via a small implant, slightly larger than a microchip. This implant slowly releases the medication under the skin over a period of up to six months. The study is placebo-controlled, with two-thirds of the participating cats receiving the drug and the remaining third serving as a control group. Researchers will monitor the cats for three months, with owners having the option to extend participation for an additional three months.
Dr. Gilor, a veterinary professor with two decades of experience working with GLP-1 drugs, explained that his initial research focused on treating feline diabetes. Still, he and others recognized the potential of these drugs to address obesity as well. He noted that studying obesity is often more straightforward than studying diabetes in cats, as approximately 80% of diabetic cats have Type 2 diabetes, although dogs predominantly develop Type 1.
Preventing Diabetes as a Primary Goal
“I’m doing this to treat obesity in cats, but the urgency for me is preventing diabetes,” Dr. Gilor stated. He highlighted the difficult reality that many cats are euthanized upon diagnosis with diabetes due to the challenges of administering twice-daily insulin injections. “I’m trying to prevent death from happening,” he added.
Veterinarians emphasize the broader health implications of obesity in cats. Dr. Kaela Navarro, an associate veterinarian at Suburban Animal Hospital in Gainesville, noted that overweight cats can experience greasy coats and skin irritation due to their inability to groom themselves effectively. Dr. Kimberly Hall de Vries, a veterinarian at Newberry Animal Hospital in Spring Hill, explained that obesity increases the risk of diabetes, joint problems, urinary issues, certain cancers, and cardiovascular stress. She described an ideal feline physique as having an “hourglass waist,” where ribs are palpable with gentle pressure.
Potential Risks and Owner Concerns
While promising, the MEOW-1 implant is not without potential concerns. Dr. Hall de Vries cautioned that cats could experience an inflammatory reaction to the implant, potentially increasing the risk of tumors. However, researchers believe the implant material itself is inert and that any inflammation would likely be triggered by the medication, not the implant itself. Dr. Gilor expressed confidence in the safety of the implant, stating, “The capsule that we’re using… is completely inert. It doesn’t cause any inflammation.”
Some veterinarians, like Dr. Navarro, are also monitoring for potential appetite suppression in cats receiving MEOW-1, recognizing that owners may be concerned about their pets losing interest in food. Steven Schwartz, a cat owner, echoed this sentiment, stating, “I don’t know that they demand it… As long as they at least demonstrate that they’re enjoying their life.”
Looking Ahead
Early results from the study are encouraging, with cats receiving the implant showing weight loss while the placebo group has not. Final results are expected this summer, and if successful, researchers plan to seek approval from the U.S. Food and Drug Administration within 18 to 24 months. If approved, MEOW-1 could be commercially available as early as 2028.
This research represents a significant step toward addressing the growing problem of pet obesity and its associated health risks. As the study progresses, further data will be crucial in determining the long-term safety and effectiveness of this novel approach to feline weight management.
What are your thoughts on using medication to manage weight in pets? Share your opinions in the comments below.
Disclaimer: This article provides informational content and should not be considered a substitute for professional veterinary advice. Always consult with a qualified veterinarian regarding the health and treatment of your pet.
